Focused On-demand Library for Rho guanine nucleotide exchange factor 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.







Alternative names:

115 kDa guanine nucleotide exchange factor; Sub1.5

Alternative UPACC:

Q92888; O00513; Q6NX52; Q8N4J4; Q96BF4; Q96F17; Q9BSB1


Rho guanine nucleotide exchange factor 1, also known as a 115 kDa guanine nucleotide exchange factor or Sub1.5, plays a pivotal role in cellular processes by regulating RhoA GTPase activity. It functions as a GTPase-activating protein for GNA12 and GNA13, and as a guanine nucleotide exchange factor for RhoA GTPase, facilitating the regulation of RhoA GTPase by guanine nucleotide-binding alpha-12 and alpha-13 subunits.

Therapeutic significance:

Linked to Immunodeficiency 62, a primary immunologic disorder characterized by recurrent severe respiratory infections, Rho guanine nucleotide exchange factor 1's involvement in immune system regulation highlights its potential as a target for therapeutic intervention. Understanding its role could open doors to novel treatments for antibody deficiencies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.